Clinical Trial Detail

NCT ID NCT02595892
Title Gemcitabine Hydrochloride Alone or With VX-970 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Recruitment Active, not recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

fallopian tube cancer

peritoneum cancer

ovarian cancer

Therapies

Berzosertib

Gemcitabine

Age Groups: adult

No variant requirements are available.